ColoVantage®: the first blood test to aid the detection of colorectal cancer in patients non-adherent to current testing approaches.
Colon cancer is the second leading cause of cancer deaths in the United States, but is often treatable when caught in early stages. Sixty percent of colon cancer deaths could be prevented if people were screened as indicated by guidelines, according to the U.S. Centers for Disease Control and Prevention. However, nearly one in three men and women age 50 and over have not been screened. Quest Diagnostics introduced ColoVantage®, a blood test that detects methylated DNA from the Septin 9 gene, a marker for colorectal cancer, that can help with detection of colorectal cancer in patients that have avoided established colorectal cancer screening tests such as colonoscopy, fecal occult blood tests, and fecal immunochemical tests (FITs). ColoVantage is not a replacement test for colonoscopy.